학술논문

Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial
Document Type
Article
Source
In The Lancet Respiratory Medicine October 2021 9(10):1111-1120
Subject
Primary Research
Articles
Language
ISSN
2213-2600